Davidson Michael H. — SEC Form 4 filings

SEC reporting owner CIK 1573785. 17 Form 4 filings on record with FilingPulse; latest filed 2026-09-15.

Transaction summary — filings shown

Covers all 17 filings on record, filed 2024-06-24 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
NewAmsterdam Pharma Co N.V. (NAMS)Chief Executive Officer, Director93 legs · 20,000 sh · $394,15810 legs · 773,840 sh · $25,328,34917
TENAX THERAPEUTICS, INC. (TENX)Director41 leg · 2,500 sh5
BioAge Labs, Inc. (BIOA)Director34
Silence Therapeutics plc (SLN)Director11

Form 4 filings — Davidson Michael H.

FiledFormIssuerReported transactionsSource
2026-09-154NewAmsterdam Pharma Co N.V. (NAMS)Purchase (P): 10,000 @ $22.65EDGAR
2026-06-124BioAge Labs, Inc. (BIOA)Grant/award (A): 22,000 (derivative) @ $0EDGAR
2026-03-024NewAmsterdam Pharma Co N.V. (NAMS)Option exercise (M): 443,707 · Sale (S): 443,707 @ $33.25 · Option exercise (M): 443,707 (derivative) @ $0EDGAR
2026-02-264NewAmsterdam Pharma Co N.V. (NAMS)Option exercise (M): 64,708 · Sale (S): 61,547 @ $36.13 · Sale (S): 3,161 @ $36.46 · Option exercise (M): 58,253 · Sale (S): 46,517 @ $35.11 · Sale (S): 10,436 @ $35.96 · +7 moreEDGAR
2026-01-134TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-01-094NewAmsterdam Pharma Co N.V. (NAMS)Sale (S): 11,582 · Grant/award (A): 81,000 · Grant/award (A): 364,000 (derivative) @ $0EDGAR
2025-07-034TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2025-06-094BioAge Labs, Inc. (BIOA)Grant/award (A): 22,000 (derivative) @ $0EDGAR
2025-03-284NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 30,992 @ $0 · Option exercise (M): 38,394 @ $0 · Sale (S): 12,258 · Grant/award (A): 38,394 (derivative) · Option exercise (M): 38,394 (derivative)EDGAR
2025-01-074NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 123,529 · Grant/award (A): 670,467 (derivative) @ $0EDGAR
2025-01-064Silence Therapeutics plc (SLN)Grant/award (A): 48,000 (derivative) @ $0EDGAR
2024-12-124TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 100,000 (derivative) @ $0EDGAR
2024-10-114NewAmsterdam Pharma Co N.V. (NAMS)Gift (G): 15,000 (derivative) @ $11.50EDGAR
2024-09-274BioAge Labs, Inc. (BIOA)Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 33,986 (derivative) @ $0EDGAR
2024-08-224NewAmsterdam Pharma Co N.V. (NAMS)Purchase (P): 5,000 @ $16.27EDGAR
2024-08-084TENAX THERAPEUTICS, INC. (TENX)Purchase (P): 2,500 · Purchase (P): 47,500 (derivative) · Purchase (P): 25,000 (derivative)EDGAR
2024-06-244NewAmsterdam Pharma Co N.V. (NAMS)Purchase (P): 5,000 @ $17.26EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1573785 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →